


Epigenetics & CVD Risk Prediction

Myriam Fornage, PhD

University of Texas Health Science Center at Houston


The Epigenome in Health and Disease

- **Epigenome:** Set of stable alterations to the DNA and histone proteins that **alter gene expression** without change in the DNA sequence
- The epigenome as a link between the genome, the environment, and phenotypes of health & disease
 - May mediate the long-term impact of environmental exposures on disease risk



DNA Methylation

- is the most studied epigenetic mark
 - covalent binding of a methyl group to the 5' carbon of cytosines occurring mainly at CpG dinucleotide sequences
 - ~30 millions CpG across the human genome and 70% of them are methylated
- plays a critical role in the regulation of gene expression
 - modulates expression of genetic information by modifying DNA accessibility to the transcriptional machinery
- is dynamic, tissue- or cell-specific, and can be influenced by, both, genes and the environment
- can be measured reliably, quantitatively, in a cost-effective manner via DNAm array



Pre-requisites for Risk Score Application




Epigenome-Wide DNA Methylation Studies (EWAS)

- **Goal:** The **integration** of DNA methylation data into our population-based research with the goal of **discovering relationships** between variation in **DNA methylation with environmental exposures, genetic variation, and disease risk** and disease-related traits
- Genome-wide association studies of DNAm and environmental exposures
 - DNA methylation signatures of cigarette smoking, alcohol intake, dietary vitamins intake, air pollution, dietary patterns
- Genome-wide association studies of DNAm and disease and disease-related traits
 - EWAS of blood pressure, circulating markers of inflammation, depressive symptoms, cognitive function, brain MRI traits
- GWAS of DNAm levels: Mapping of *cis* and *trans* meQTL

EWAS vs. GWAS

- Genetic factors are fixed throughout the lifetime
 - No assumption about temporality of effects
 - No issue with time of sample collection
 - Genetic factors can be assumed to be randomly assigned with respect to traits
 - Population stratification is identifiable and can be corrected
 - Pattern of correlation (LD) well defined in genetic data
- DNA methylation is a dynamic process
 - Collection timing matter: Optimal timing of the measurement relative to outcome of interest?
 - Issues of reverse causation need to be carefully assessed
 - Confounding is often present
 - Cellular heterogeneity
 - Measured and unmeasured environmental factors
 - Inter-correlation of CpGs not well-defined or exploited
 - DNAm is the dependent variable in EWAS studies



Study Design and Methodologies: Blood Pressure EWAS



EWAS of Blood Pressure – CHARGE Consortium

Discovery sample: 9,828 middle-aged to older adults (EA, N = 6650; AA, N = 3178) from 9 cohorts


Replication Sample: 7,182 middle-aged to older adults (EA, N = 4695; AA, N = 1458; HIS, N = 1029) from 7 cohorts



	tests, n	p-value threshold	SBP probes, n	DBP probes, n	total probes, n
Meta-Analysis					
<i>Discovery</i>	> 450,000	1E-7	25	9	31
<i>Replication</i>	31	0.0016	9	6	13
<i>Overall</i>	> 450,000	1E-7	102	56	126

EWAS of BP: Lessons Learned


- DNA methylation explains more of BP variance than genetic loci
 - DNAm score based on 13 replicated CpGs explained ~1.5% - 2% variance in BP
 - Genetic risk score based on known BP SNPs (N=261) explained between 0.003% and 0.1%
- Similar findings are observed for other traits



EWAS of BP: Lessons Learned

- Many identified BP-associated CpGs are heritable
 - replicated probes average $h^2 = 30-60\%$; epigenome-wide average $h^2 = 12\%$
- meQTLs could be identified in 10 of the 13 BP-associated CpGs
 - 9 of 13 CpGs showed substantial evidence for meQTLs in EA and AA ancestries, with evidence for weak meQTLs at one additional CpG site in each ancestry
 - Seven of the 10 meQTLs showed nominal association with BP

meQTL mapping in 4,036 EAs and 2,595 AAs and confirmed in an independent dataset (ARIES)



P-value of association of SNPs with DNAm relative to the CpG location (± 25 kb)

EWAS of BP: Lessons Learned


- DNAm influences BP but also BP influences DNAm levels
 - Evidence through bidirectional Mendelian randomization
 - Instrumental variables:
 - meQTL
 - BP-associated SNPs

Instrumental Variables:
3-10 *cis*-meQTLs ($r^2 < 0.2$)



Forward Causality
cg08035323


Instrumental Variables:
29 ICBP SNPs



Reverse Causality
cg00533891
cg00574958
cg02711608
cg22304262


EWAS of BP: Lessons Learned

- Integration of other omics (gene expression) improves interpretability of EWAS findings




Blood DNAm, blood gene expression, and BP measured in the same sample

Assessing Functional Causality: Two-Step Mendelian Randomization





Causal mediation by gene transcripts associated with DNAm & BP



Application of DNAm to (Risk) Prediction

- How well does DNAm predict cardiometabolic traits?
 - DNAm scores generated in the GS cohort (N=5087) and validated in LBC1936 cohort (N=895)
 - Near perfect discriminatory power for current smokers
 - Moderate discrimination of obesity, heavy drinking, and high HDL
 - Poor discrimination of high(college) education and high LDL




ROC analysis for DNAm predictors of smoking, alcohol, education, BMI, and lipid traits in the LBC1936 cohort

Association of DNAm risk scores, polygenic risk scores, and phenotypes with mortality


Trait	Predictor	HR	95% CI	P
Alcohol	Phenotypic	0.93	0.82 – 1.07	0.362
	Epigenetic	1.24	1.08 – 1.43	0.003
	Genetic	1.05	0.92 – 1.21	0.479
Smoking	Phenotypic (Current smoker)	1.91	0.98 – 3.70	0.057
	Epigenetic	1.29	1.05 – 1.57	0.013
	Genetic	0.98	0.86 – 1.13	0.801
Education	Phenotypic	0.9	0.78 – 1.05	0.178
	Epigenetic	0.81	0.71 – 0.93	0.004
	Genetic	0.96	0.84 – 1.11	0.59
BMI	Phenotypic	1.14	0.99 – 1.32	0.077
	Epigenetic	1.01	0.87 – 1.17	0.903
	Genetic	1.1	0.95 – 1.28	0.184
Total cholesterol	Phenotypic	0.86	0.74 - 1.00	0.047
	Epigenetic	0.98	0.83 - 1.14	0.774
	Genetic	1.14	1.00 - 1.31	0.064
HDL cholesterol	Phenotypic	0.92	0.77 - 1.09	0.324
	Epigenetic	0.92	0.78 - 1.08	0.314
	Genetic	1.08	0.94 - 1.25	0.274
LDL cholesterol	Phenotypic	0.9	0.78 - 1.05	0.176
	Epigenetic	1.01	0.86 - 1.19	0.926
	Genetic	1.1	0.95 - 1.28	0.181
Waist-to-hip ratio	Epigenetic	1.24	1.08 - 1.42	0.002
	Genetic	0.93	0.82 - 1.07	0.315
% body fat	Epigenetic	1.08	0.93 - 1.23	0.328
	Genetic	1.18	1.03 - 1.36	0.016

Application of DNAm to Age Prediction



- DNAm-based age estimators
 - Age has a strong impact on genome-wide DNAm levels
 - DNAm age estimators are based on sets of CpGs selected to best estimate chronological age
- **Age acceleration:** Deviation of the DNA methylation-predicted age from the chronological age – Index of an individual's rate of aging
- Discrepancies between a person's DNA methylation age and chronological age may be detrimental to health
 - Association between blood DNA methylation-derived measures of accelerated aging and all-cause mortality (*Marioni et al. 2015*)

Application of DNAm to Age Prediction



Conclusions

- EWAS identifies new genomic regions influencing complex traits not previously implicated by GWAS but care must be taken in the interpretation of epigenetic associations
- DNAm scores explain a substantial proportion of phenotypic variance and are able to predict health and lifestyle factors with some success
- Data suggest a potential application of DNAm signatures as proxies for self-(un)reported phenotypes, such as smoking
- DNAm age biomarkers of aging for identifying anti-aging interventions?
 - DNAm is dynamic and tissue-specific. The predictive abilities of DNAm may depend on the characteristics of the population/ tissue in which the score was derived



CHARGE
CONSORTIUM
COHORTS FOR HEART & AGING RESEARCH
IN GENOMIC EPIDEMIOLOGY

Thank you!

DNA Methylation Analysis Identifies Loci for Blood Pressure Regulation

Melissa A. Richard,^{1,52,*} Tianxiao Huan,^{2,3,52} Symen Ligthart,^{4,52} Rahul Gondalia,⁵ Min A. Jhun,⁶ Jennifer A. Brody,⁷ Marguerite R. Irvin,⁸ Riccardo Marioni,^{9,10,11} Jincheng Shen,¹² Pei-Chien Tsai,¹³ May E. Montasser,¹⁴ Yucheng Jia,¹⁵ Catriona Syme,¹⁶ Elias L. Salfati,¹⁷ Eric Boerwinkle,^{18,19} Weihua Guan,²⁰ Thomas H. Mosley, Jr.,²¹ Jan Bressler,¹⁸ Alanna C. Morrison,¹⁸ Chunyu Liu,^{2,3,22} Michael M. Mendelson,^{2,3,23} André G. Uitterlinden,²⁴ Joyce B. van Meurs,²⁴ BIOS Consortium, Oscar H. Franco,⁴ Guosheng Zhang,^{25,26,27} Yun Li,^{25,28} James D. Stewart,^{5,29} Joshua C. Bis,⁷ Bruce M. Psaty,³⁰ Yii-Der Ida Chen,¹⁵ Sharon L.R. Kardina,⁶ Wei Zhao,⁶ Stephen T. Turner,³¹ Devin Absher,³² Stella Aslibekyan,⁸ John M. Starr,^{9,33} Allan F. McRae,^{11,34} Lifang Hou,³⁵ Allan C. Just,³⁶ Joel D. Schwartz,³⁷ Pantel S. Vokonas,³⁸ Cristina Menni,¹³ Tim D. Spector,¹³ Alan Shuldiner,^{14,39} Coleen M. Damcott,¹⁴ Jerome I. Rotter,¹⁵ Walter Palmas,⁴⁰ Yongmei Liu,⁴¹ Tomáš Paus,^{42,43,44} Steve Horvath,⁴⁵ Jeffrey R. O'Connell,¹⁴ Xiuqing Guo,¹⁵ Zdenka Pausova,^{16,46} Themistocles L. Assimes,¹⁷ Nona Sotoodehnia,⁴⁷ Jennifer A. Smith,⁶ Donna K. Arnett,⁴⁸ Ian J. Deary,^{9,49} Andrea A. Baccarelli,³⁷ Jordana T. Bell,¹³ Eric Whitsel,^{5,50} Abbas Dehghan,^{4,51} Daniel Levy,^{2,3,53} and Myriam Fornage^{1,18,53,*}



- CHARGE Epigenetics Working Group